Research Papers:
Enhanced antitumor activity and cytotoxic effect on cancer stem cell population of metforminbutyrate compared with metformin HCl in breast cancer
PDF | Full Text | How to cite
Metrics: PDF 3620 views | Full Text 4276 views
Kyung-Min Lee1,2, Minju Lee2, Jiwoo Lee1,2, Sung Wuk Kim4, Hyeong-Gon Moon2,3, Dong-Young Noh2,3, Wonshik Han2,3
1Biomedical Research Institute, Seoul National University Hospital, Seoul 110-744, Republic of Korea
2Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea
3Department of Surgery, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea
4Hanall Biopharma Co., Ltd., Seoul 138-922, Republic of Korea
Correspondence to:
Wonshik Han, e-mail: [email protected]
Keywords: metformin analog, breast cancer, stem cell population, G2/M arrest, anti-cancer drug
Received: September 06, 2015 Accepted: May 05, 2016 Published: May 20, 2016
ABSTRACT
Metformin, which is a drug commonly used to treat type 2 diabetes, has shown anti-tumor effects in numerous experimental, epidemiologic, observational, and clinical studies. Here, we report a new metformin derivative, metformin-butyrate (MFB). Compared to metformin-HCl, it more potently activates AMPK, inhibits mTOR, and impairs cell cycle progression at S and G2/M phases. Moreover, MFB inhibits the mammosphere formation of breast cancer cells and shows cytotoxic effects against CD44+CD24-/low populations in vitro and in vivo, indicating that it might have preferential effects on the cancer stem cell population. MFB showed synergistic cytotoxicity with docetaxel and cisplatin, and MFB pretreatment of breast cancer cells prior to their injection into the mammary fat pads of mice significantly decreased the obtained xenograft tumor volumes, compared with untreated or metformin-pretreated cells. Overall, MFB showed greater anti-neoplastic activity and greater efficacies in targeting the G2/M phase and breast cancer stem cell population, compared to metformin-HCl. This suggests that MFB may be a promising therapeutic agent against aggressive and resistant breast cancers.